Mn Services Vermogensbeheer B.V. Sells 4,100 Shares of Zoetis Inc. (NYSE:ZTS)

Mn Services Vermogensbeheer B.V. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 181,503 shares of the company’s stock after selling 4,100 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Zoetis were worth $31,465,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Focus Financial Network Inc. ADV acquired a new position in shares of Zoetis in the 4th quarter valued at about $2,159,000. Price T Rowe Associates Inc. MD increased its holdings in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Axiom Investors LLC DE lifted its stake in Zoetis by 36.3% in the fourth quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock valued at $117,331,000 after buying an additional 158,459 shares during the period. Global Assets Advisory LLC bought a new position in shares of Zoetis during the 1st quarter worth approximately $8,831,000. Finally, Cary Street Partners Investment Advisory LLC grew its position in shares of Zoetis by 3.3% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 96,810 shares of the company’s stock worth $19,107,000 after buying an additional 3,075 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 0.7 %

Shares of ZTS stock traded down $1.27 during trading hours on Friday, reaching $180.90. The company had a trading volume of 1,262,412 shares, compared to its average volume of 1,969,611. The business has a fifty day simple moving average of $178.56 and a 200-day simple moving average of $174.94. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a market cap of $81.96 billion, a price-to-earnings ratio of 34.86, a price-to-earnings-growth ratio of 2.79 and a beta of 0.86. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.41 EPS. On average, research analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. HSBC dropped their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Stifel Nicolaus boosted their target price on Zoetis from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, August 5th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Piper Sandler raised their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.